Why Might My Dermatologist Recommend PDT Over Other AK Treatments?

Introduction

There is no single best treatment for actinic keratosis (AK) — only the treatment that best fits a particular patient's pattern of sun damage, lifestyle, and priorities. Dermatologists generally choose between spot treatment of individual lesions (cryotherapy), a broader field-directed approach applied at home over weeks (topical creams), and photodynamic therapy (PDT), which treats a whole field of damaged skin in one or two office visits. This article walks through how PDT stacks up against the other two on the questions patients usually care about most: how well it works, how much time and discomfort it involves, and how the skin looks afterward.

For a plain-language explanation of how PDT itself works, see what photodynamic therapy is and how it works.

PDT vs. Cryotherapy

Cryotherapy — a quick freeze with liquid nitrogen — is the fastest way to treat a small number of individual AKs, and it remains the most common AK treatment overall. It's well suited to a handful of scattered, easily identified lesions. Its limits show up when there are many AKs, or when the surrounding skin carries subclinical sun damage that hasn't yet become a visible lesion: cryotherapy only treats what the dermatologist can see and freeze, one spot at a time, and repeated freezing over the years can leave patches of hypopigmentation or scarring.

A randomized trial comparing the two head-to-head found a 91% lesion response rate with PDT versus 68% with a single cycle of cryotherapy at three months, along with a better cosmetic outcome and stronger patient preference for PDT. Larger pooled analyses across many trials tell a more nuanced story — overall clearance rates between PDT and cryotherapy are often statistically similar — but PDT has shown a clear edge for thicker, more advanced AKs and consistently produces less hypopigmentation than repeated freezing.

PDT vs. Topical Field Therapy

Topical field therapies — 5-fluorouracil, imiquimod, and diclofenac gel — are creams patients apply themselves at home over a course that can run anywhere from two to sixteen weeks, depending on the medication and regimen. They treat the whole field, much like PDT, but the mechanism and time commitment are very different: the skin goes through a stretch of expected redness, irritation, crusting, and sometimes real discomfort that builds gradually over the application period, rather than the shorter, more intense reaction PDT produces in the days right after a single office visit.

In pooled trial data, 5-fluorouracil clears more lesions than PDT at 12 months in a typical immunocompetent patient, and imiquimod has also outperformed PDT in that same population. So on raw 12-month clearance alone, a topical cream is often the more effective option for an otherwise healthy patient. PDT's advantages lie in the details many patients weigh just as heavily: it compresses field treatment into one or two supervised visits instead of a weeks-long course of self-applied medication, it has produced meaningfully higher patient satisfaction scores than imiquimod in head-to-head comparisons, and — notably — it has shown superior efficacy specifically in organ transplant recipients and other immunosuppressed patients, who carry a much higher lifetime risk of AKs progressing to squamous cell carcinoma.

The two approaches aren't always either/or. Pretreating skin with a short course of topical 5-fluorouracil before a PDT session has been shown to increase how much photosensitizer the treated cells take up, improving clearance rates beyond what either treatment achieves alone — an option worth raising if your dermatologist hasn't already mentioned it.

Conclusion

No single AK treatment wins on every measure. Topical creams often clear more lesions over a year in an otherwise healthy patient; cryotherapy remains the fastest option for a few isolated spots; PDT trades a more involved single visit for whole-field treatment, a favorable cosmetic result, and a clear efficacy edge in immunosuppressed patients. The right choice depends on how many AKs you have, where they are, your immune status, and how you'd rather spend your treatment time — a conversation worth having directly with your dermatologist.